Compare · NVO vs OKUR
NVO vs OKUR
Side-by-side comparison of Novo Nordisk A/S (NVO) and OnKure Therapeutics Inc. (OKUR): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and OKUR operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $222.81B, about 1313.3x OKUR ($169.7M).
- Over the past year, NVO is down 21.8% and OKUR is up 82.2% - OKUR leads by 104.0 points.
- NVO has been more active in the news (5 items in the past 4 weeks vs 3 for OKUR).
- NVO has more recent analyst coverage (25 ratings vs 3 for OKUR).
- Company
- Novo Nordisk A/S
- OnKure Therapeutics Inc.
- Price
- $50.31-2.25%
- $4.19+2.07%
- Market cap
- $222.81B
- $169.7M
- 1M return
- +15.47%
- -1.64%
- 1Y return
- -21.78%
- +82.17%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 5
- 3
- Recent ratings
- 25
- 3
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
Latest OKUR
- OnKure Therapeutics to Host Virtual KOL Event to Discuss PI3Kα Inhibitor Medicines: Selectivity Matters & Pan-Mutant Allosteric Inhibition Delivers, on July 15, 2026
- President and CEO Saccomano Nicholas A sold $378 worth of shares (86 units at $4.40), decreasing direct ownership by 0.76% to 11,247 units (SEC Form 4) (for tax liability)
- Chief Financial Officer Leverone Jason A. sold $1,332 worth of shares (303 units at $4.40), decreasing direct ownership by 2% to 18,802 units (SEC Form 4) (for tax liability)
- SEC Form 4 filed by Director Mathers Edward T
- SEC Form 4 filed by Director Ratcliffe Liam
- SEC Form 4 filed by Director Phillips Andrew John
- SEC Form 4 filed by Director Jansen Valerie Malyvanh
- SEC Form 4 filed by Director Grey Michael G
- SEC Form 4 filed by Director Carruthers R Michael
- SEC Form S-8 filed by OnKure Therapeutics Inc.